JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)
JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)1. Shift From “Weight Loss” to Chronic Metabolic DiseaseDay 3 discussions made it clear that industry messaging is moving away from cosmetic weight loss and toward lifelong metabolic disease management.Key framing heard repeatedly:Obesity as a multisystem, chronic diseaseGLP-1–based therapies positioned alongside statins or antihypertensives, […]
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A
This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. It’s Day 3 of JPM and all of us — Matt, Elaine, Adam, and Allison — are still here! Also, surprisingly, it’s not raining here in San Francisco, as it usually is around JPM. (Remember the umbrellas?) The Readout Loud […]
FDA asks that suicide warning labels be taken off GLP-1 weight-loss drugs
The Food and Drug Administration said Tuesday that it wants suicide warning labels on GLP-1 weight-loss drugs to be removed.
Mission Foods: NEW YEAR, NEW NUTRITION PLAN!
From GLP-1 to Keto, hear the nutrition tips and recipes you need to stay on track in the New Year IRVING, Texas, Jan. 14, 2026 /PRNewswire/ — BACKGROUND: As the calendar turns from December to January, millions of Americans vow that this will be the year they stick to their New Year’s…
Compounding pharmacy sues Lilly, Novo over GLP-1 drug competition
Post Content
Food Companies Are Targeting Users of Weight-Loss Drugs With ‘GLP-1 Friendly’ Labels
But the labels — unlike the popular medications themselves — aren’t regulated by the FDA.
Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety
by Ariana M. Chao, Adam Gilden, Thomas A. Wadden Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care. In this Perspective, Ariana Chao, Adam Gilden and Thomas Wadden […]
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value in recent years. It has a leading GLP-1 drug that’s approved for diabetes (Mounjaro) and weight loss (Zepbound). Those products are generating billions in revenue for the business every quarter. What’s encouraging, however, […]
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Novo Nordisk’s CEO spoke about GLP-1 pricing and Pfizer’s CEO spoke about the company’s obesity ambitions while at the JPMorgan Healthcare Conference.
Who’s Most Likely to See Hair Loss on GLP-1s?
We have heard Reddit horror stories about GLP-1 users losing their hair. Now, there’s finally a study corroborating these claims. The researchers concluded that patients with pre-existing hair loss might be at risk of losing more hair while using these drugs. — ULO HAIR GROWTH OFFERINGS (15% OFF, FOREVER): https://ulo.co/discount/perfecthairhealth15 Not sure where to start […]